)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cognition Therapeutics
Cognition Therapeutics (CGTX) investor relations material
Cognition Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
FDA feedback aligned key elements of a planned zervimesine registrational study in DLB, with a mid-2027 start targeted.
Q3 net loss narrowed year over year to $4.1M; cash, grants and offering proceeds are expected to support operations into Q4 2027, assuming no 2025 ATM use.
Financial highlights
Q3 2026 R&D expense was $5.1M vs. $3.8M in Q3 2025, driven by higher CRO trial activity and professional fees.
Q3 2026 G&A expense was $2.3M vs. $2.6M in Q3 2025, primarily reflecting lower professional fees and compensation.
Q3 net loss was $4.1M, or $0.04 per basic and diluted share, vs. $4.9M, or $0.06 per share, in Q3 2025.
9M operating expenses were $23.9M vs. $34.1M; net loss was $12.6M vs. $20.1M year over year.
Q3 operating expenses were $7.4M vs. $6.4M; total other income, primarily grants, was $3.2M vs. $1.4M.
Outlook and guidance
START enrolled 545 participants; top-line results in mild cognitive impairment and early Alzheimer’s disease are expected in H2 2027, after all participants complete 18 months of treatment.
Current cash is expected to fund operations and capital expenditures into Q4 2027; the estimate includes non-dilutive grants and offering proceeds and assumes no 2025 ATM use.
Manufacturing, site selection, patient recruitment and protocol finalization remain under evaluation for the planned DLB study.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cognition Therapeutics
- Advancing zervimesine for DLB psychosis with strong Phase 2 data and FDA alignment.CGTX
Investor presentation - Net loss improved to $3.9M in Q2 2026, with strong cash position and extended patent protection.CGTXQ2 2026
- Phase II trials showed strong efficacy and safety, with Phase III and partnerships in focus.CGTXLife Sciences Investor Forum
- Directors and auditor were elected by majority vote at a virtual annual meeting, with Q&A after.CGTXAGM 2026
- Oral therapy for Lewy body dementia psychosis shows strong efficacy and safety in phase II trials.CGTXJefferies Global Healthcare Conference 2026
- Advancing zervimesine for DLB psychosis with strong efficacy, safety, and regulatory support.CGTXInvestor presentation
- Q1 2026 net loss narrowed to $4.6M as R&D costs fell, with $31.2M cash and clinical progress.CGTXQ1 2026
- Board recommends director elections and auditor ratification, highlighting governance and ESG.CGTXProxy filing
- CT1812 slowed cognitive decline by up to 108% in patients with low plasma p-tau217, supporting phase 3 trials.CGTXStudy Update
Next Cognition Therapeutics earnings date
Q4 202624 Mar, 2027
Cognition Therapeutics
Next Cognition Therapeutics earnings date
Q4 202624 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cognition Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule therapeutics aimed at treating age-related degenerative diseases and disorders affecting the central nervous system and retina. The company's research focuses on developing a portfolio of small molecule product candidates targeting the sigma-2 receptor (S2R) complex. This receptor complex is a crucial regulator of the cellular damage response for conditions such as Alzheimer's disease , dry age-related macular degeneration (dry AMD), geographic atrophy, among others. Cognition Therapeutics is headquartered in Purchase, New York, and its shares are listed on the Nasdaq.